Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 30.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,480,172 shares of the company’s stock after buying an additional 344,373 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Amneal Pharmaceuticals were worth $18,739,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AMRX. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth $31,000. Spire Wealth Management grew its holdings in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth $42,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at $50,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $12.48 on Friday. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $15.42. The firm has a market cap of $3.93 billion, a PE ratio of 54.26 and a beta of 1.32. The firm’s 50 day moving average price is $13.48 and its two-hundred day moving average price is $12.26.

Analysts Set New Price Targets

A number of analysts have commented on AMRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 6th. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Finally, Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.